Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Nystrm T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrn B, Sjholm A: Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
Among the 14 trials included, four excluded patients with heart failure, while the remaining nine articles excluded patients with heart failure, cardiac events (e.g., myocardial infarction, unstable angina, revascularization procedure, stroke) or cardiovascular diseases ( Supplementary Table 4 )
Ideal candidates typically include patients with: Type 2 diabetes and NAFLD/MASLD : This represents the most straightforward indication, as GLP-1 agonists are FDA-approved for diabetes management
In endothelial cells, arginine oxidation produces nitric oxide (NO) and L-citrulline
Validation of multiple mechanisms of tirzepatide treatment in MAFLD mice To further elucidate the molecular mechanisms by which tirzepatide treats MAFLD in mice, we conducted PRM experiments on liver tissues to verify the reliability of protein expression levels
US$ 26.60
.png)
US$ 29.14
US$ 26.77
